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Abstract
 
The discovery of dendritic cell (DC)-specific intercellular adhesion molecule (ICAM)-3–grabbing
 
nonintegrin
 
 
 
(DC-SIGN) as a DC-specific ICAM-3 binding receptor that enhances HIV-1 infec-
 
tion of T cells in
 
 
 
trans has indicated a potentially important role for adhesion molecules in AIDS
pathogenesis. A related molecule called DC-SIGNR exhibits 77% amino acid sequence identity
with DC-SIGN. The 
 
DC-SIGN 
 
and 
 
DC-SIGNR 
 
genes map within a 30-kb region on chromo-
some 19p13.2-3. Their strong homology and close physical location indicate a recent duplication
of the original gene. Messenger RNA and protein expression patterns demonstrate that the DC-
SIGN–related molecule is highly expressed on liver sinusoidal cells and in the lymph node but not
on DCs, in contrast to DC-SIGN. Therefore, we suggest that a more appropriate name for the
DC-SIGN–related molecule is L-SIGN, liver/lymph node–specific ICAM-3–grabbing noninte-
grin. We show that in the liver, L-SIGN is expressed by sinusoidal endothelial cells. Functional
studies indicate that L-SIGN behaves similarly to DC-SIGN in that it has a high affinity for
ICAM-3, captures HIV-1 through gp120 binding, and enhances HIV-1 infection of T cells in
trans. We propose that L-SIGN may play an important role in the interaction between liver sinu-
soidal endothelium and trafficking lymphocytes, as well as function in the pathogenesis of HIV-1.
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Introduction
 
Dendritic cell (DC)
 
1
 
-specific intercellular adhesion mole-
 
cule (ICAM)-3–grabbing nonintegrin
 
 (
 
DC-SIGN) has re-
cently been identified as a DC-specific adhesion receptor
that mediates the interaction between DCs and resting T
cells through high affinity binding to ICAM-3, thereby fa-
cilitating the initiation of primary immune responses (1, 2).
DC-SIGN was shown to be identical to the previously re-
ported type II membrane-associated C-type lectin (2) that
binds HIV-1 envelope glycoprotein gp120 in a CD4-inde-
pendent manner (3). The affinity of DC-SIGN exceeds that
of CD4 for HIV-1 gp120 (3), and upon capture of HIV-1,
DC-SIGN does not appear to promote viral entry into the
 
DC itself, but rather enhances infection of T cells in
 
 
 
trans
(1). DC-SIGN–associated HIV-1 remains infectious over a
prolonged period of time, perhaps contributing to the in-
fectious potential of the virus during its transport by DCs
from the periphery to lymphoid organs.
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Abbreviations used in this paper:
 
 CCR, CC chemokine receptor; DC,
dendritic cell; DC-SIGN, DC-specific ICAM-3–grabbing nonintegrin;
EST, expressed sequence tag; ICAM, intercellular adhesion molecule;
L-SIGN, liver/lymph node–specific ICAM-3–grabbing nonintegrin;
LSEC, liver sinusoidal endothelial cell; nt, nucleotides; RH, radiation hy-
brid; RT, reverse transcription; UTR, untranslated region. 
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Expression and Functional Characterization of a DC SIGN–related Protein
 
A previous search by Yokoyama-Kobayashi et al. (4) for
cDNA clones encoding type II membrane proteins resulted
in the identification of a partial clone that was homologous,
but not identical, to the cDNA encoding the molecule
now known as DC-SIGN. The putative protein product
contained a deletion of 28 amino acids in the cytoplasmic
domain and was lacking the entire C-type lectin domain
relative to the cDNA encoding DC-SIGN. More recently,
Soilleux et al. (5) described the full-length cDNA sequence
of the related gene, which they called 
 
DC-SIGNR
 
. The
genomic organization of 
 
DC-SIGN
 
 and 
 
DC-SIGNR
 
 was
compared, indicating a high degree of similarity. Con-
comitant expression of the two genes in placenta, en-
dometrium, and stimulated KG1 cells (a cell line that
phenotypically resembles myeloid DCs) was observed, al-
though the expression of 
 
DC-SIGNR
 
 was very low in both
endometrium and stimulated KG1 cells (5).
While attempting to identify polymorphisms in the 
 
DC-
SIGN
 
 gene, we also discovered the gene corresponding to
the partial cDNA sequence described by Yokoyama-Koba-
yashi et al. (4). Tissue expression patterns of the 
 
DC-
SIGNR
 
 gene indicated that it is expressed at considerably
high levels in only two tissues, liver and lymph node, but
not in monocyte-derived DCs. Therefore, we have called
the molecule L-SIGN, liver/lymph node–specific ICAM-
3–grabbing nonintegrin, which we believe more accurately
depicts the function and expression pattern of this molecule
than does DC-SIGNR. Here we refine the genomic orga-
nization of the 
 
SIGN
 
 gene complex, and also report the
tissue distribution and functional characterization of the
L-SIGN molecule.
 
Materials and Methods
 
Characterization of DC-SIGN and L-SIGN cDNA. 
 
We have
submitted the full 
 
DC-SIGN
 
 and 
 
L-SIGN
 
 cDNA sequences to
GenBank/EMBL/DDBJ under accession nos. AF290886 and
AF290887, respectively. The 
 
L-SIGN
 
 cDNA sequence represents
a variant containing six repeats in exon 4. The 5
 
9
 
 and 3
 
9
 
 ends of
the transcripts (except the 3
 
9 
 
end of the 
 
DC-SIGN
 
 mRNA) were
determined by 5
 
9
 
 rapid amplification of cDNA ends
 
 (
 
RACE;
CLONTECH Laboratories, Inc.). The length of the 3
 
9
 
 end of the
 
DC-SIGN
 
 mRNA was estimated based on Northern blot analysis
data (transcript size) and reverse transcription (RT)-PCR data us-
ing forward primers specific for the 1.3-kb 
 
DC-SIGN
 
 cDNA se-
quence (3) and reverse primers specific for several GenBank/
EMBL/DDBJ expressed sequence tags (ESTs) (e.g., AI472111
and AA454170), mapping downstream of the alleged 3
 
9
 
 end of
 
DC-SIGN
 
. A cDNA fragment containing the full coding se-
quence of 
 
L-SIGN 
 
(nucleotides [nt] 39–1184, GenBank/EMBL/
DDBJ accession no. AF290887) was amplified from human pla-
cental mRNA (CLONTECH Laboratories, Inc.) and cloned into
the expression vectors pcDNA3.1/V5-His/TOPO (pcDNA3-
L-SIGN) and pCDM8 (pCDM8-L-SIGN).
 
Radiation Hybrid Mapping.
 
PCR-based radiation hybrid (RH)
mapping with 
 
DC-SIGN
 
– and 
 
L-SIGN
 
–specific primers was per-
formed using the Genebridge 4 RH panel (Research Genetics).
The PCR results were submitted to the Gene Map server at the
Sanger Center (http://www.sanger.ac.uk/Software/Rhserver).
The chromosomal position of markers linked to the genes was
 
determined searching the Genatlas database (http://web.citi2.fr/
GENATLAS) and the genetic map of human chromosome
19 provided by the Marshfield Clinic (http://research.
marshfieldclinic.org/genetics/).
 
Genotype Analysis of L-SIGN and DC-SIGN Exon4. 
 
The
repeat region in exon 4 was amplified with the following pairs of
primers: L28, TGTCCAAGGTCCCCAGCTCCC, and L32,
GAACTCACCAAATGCAGTCTTCAAATC, for 
 
L-SIGN
 
;
DL27, TGTCCAAGGTCCCCAGCTCC, and DI4R, CCC-
CGTGTTCTCATTTCACAG, for 
 
DC-SIGN
 
. The cycle con-
ditions were as follows: 94
 
8
 
C for 5 s and 68
 
8
 
C for 1 min. Alleles
were distinguished by agarose gel electrophoresis and ethidium
bromide staining.
 
Northern Blot Analysis.
 
Total RNA from cultured human im-
mature DCs (see below) was isolated using Trizol (Life Technol-
ogies). 10 
 
m
 
g of the isolated RNA was electrophoresed on a 1%
agarose gel, transferred to Hybond-XL (Amersham Pharmacia
Biotech) as described (6), and used for Northern blot analysis
along with two human multiple tissue Northern blots (CLON-
TECH
 
 
 
Laboratories, Inc.). Three probes were subsequently hy-
bridized to the blots: (1) an 
 
L-SIGN
 
–specific probe (nt 100–183,
GenBank/EMBL/DDBJ accession no. AF290887); (2) a probe
recognizing both 
 
DC-SIGN 
 
and 
 
L-SIGN 
 
(nt 1–1233, GenBank/
EMBL/DDBJ accession no. AF290886); and (3) an actin control
probe (CLONTECH Laboratories, Inc.). Hybridization proce-
dures were performed according to manufacturer specifications
(CLONTECH Laboratories, Inc.).
 
Antibodies.
 
Anti–DC-SIGN mAbs AZN-D1 and AZN-D2
were described previously (2). mAb AZN-D3 was obtained by
screening hybridoma supernatants of BALB/c mice immunized
with THP-1–DC-SIGN cells (1) for the ability to stain both DC-
SIGN and L-SIGN. Anti–DC-SIGN mAb AZN-D2 also cross-
reacts with L-SIGN, as was initially determined by the staining of
K562–L-SIGN cells (data not shown). Anti–L-SIGN rabbit anti-
serum was generated by immunization with two L-SIGN–spe-
cific peptides, PTTSGIRLFPRD and WNDNRCDVDNYW
(Veritas, Inc. Laboratories).
 
Cells.
 
DCs were cultured from monocytes in the presence of
500 U/ml IL-4 and 800 U/ml GM-CSF (Schering-Plough; ref-
erences 7 and 8). At day 7 the cells expressed high levels of MHC
class I and II, 
 
a
 
M
 
b
 
2 (CD11b), 
 
a
 
X
 
b
 
2 (CD11c), DC-SIGN and
ICAM-1, moderate levels of LFA-1 and CD86, and low levels of
CD14, as measured by flow cytometry. Stable K562 transfectants
expressing L-SIGN (K562–L-SIGN) were generated by cotrans-
fection of K562 with the pCDM8–L-SIGN plasmid and the
pGK-neo vector by electroporation (9). Stable K562–DC-SIGN
transfectants were generated in a similar manner using pRc/
CMV–DC-SIGN (2). THP-1–DC-SIGN cells were described
previously (2). Stable THP-1–L-SIGN transfectants were gener-
ated by electroporation of THP-1 cells with pcDNA3–L-SIGN,
selection for G418 resistance, and positive sorting for L-SIGN
expression using mAb AZN-D3. All cell lines were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum in addi-
tion to specific cytokine or antibiotic requirements as indicated.
K562 and THP-1 are monocytic cell lines. HEK293T are human
embryonic kidney cells containing a single temperature-sensitive
allele of SV-40 large T antigen. GHOST cells are HIV-indicator
cells derived from human osteosarcoma cells (10). Hut/CC
chemokine receptor (CCR)5 cells are the transformed human T
cell line Hut78 stably transduced with CCR5.
 
Fluorescent Beads Adhesion Assay.
 
Carboxylate-modified
TransFluorSpheres (488/645 nm, 1.0 
 
m
 
m; Molecular Probes)
were coated with ICAM-3 as described previously for ICAM-1 
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(11). Fluorescent beads were coated with M-tropic HIV-1
 
MN
 
 en-
velope glycoprotein gp120 as follows: streptavidin-coated fluo-
rescent beads were incubated with biotinylated F(ab
 
9
 
)
 
2
 
 fragment
rabbit anti–sheep IgG (6 
 
m
 
g/ml; Jackson ImmunoResearch Lab-
oratories) followed by an overnight incubation with sheep anti-
gp120 antibody D7324 (Alto Bio Reagents, Ltd.) at 4
 
8
 
C. The
beads were washed and incubated with 250 ng/ml purified HIV-1
gp120 (provided by Immunodiagnostics, Inc., through the Na-
tional Institutes of Health AIDS Research and Reference Re-
agent Program) overnight at 4
 
8
 
C. The fluorescent beads adhesion
assay was performed as described by Geijtenbeek et al. (11). In
brief, cells were resuspended in adhesion buffer (20 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
, 0.5%
BSA) at a final concentration of 5
 
 3 
 
10
 
6
 
 cells/ml. 50,000 cells
were preincubated with mAb (20 
 
m
 
g/ml) for 10 min at room
temperature. Ligand-coated fluorescent beads (20 beads/cell)
were added and the suspension was incubated for 30 min at 37
 
8
 
C.
Adhesion was determined by measuring the percentage of cells
that bound fluorescent beads using flow cytometry on a FAC-
Scan™ (Becton Dickinson).
 
Detection of L-SIGN on Primary Human Liver Sinusoidal Endothe-
lial Cells.
 
Liver tissue
 
 
 
was obtained from a patient undergoing
liver surgery after having received written consent. Isolation of pri-
mary human liver cells was performed as described previously (12).
Cells were cultured on collagen type I–coated tissue culture plates
in supplemented Williams E Medium (13). The day after isolation,
liver cells were incubated with Texas red–labeled OVA (10 
 
m
 
g/
ml; Molecular Probes) for 2 h and detached from the matrix by
gentle trypsin treatment. Cells were stained with rabbit anti–
L-SIGN antiserum followed by goat anti–rabbit Ig FITC (Di-
anova) and analyzed with a FACScan™ (Becton Dickinson) using
CELLQuest™ software. OVA uptake was characteristic of liver si-
nusoidal endothelial cells (LSECs) only and not Kupffer cells, as
verified by the costaining of OVA
 
1
 
 cells with an endothelial cell–
specific marker, acetylated LDL, using confocal microscopy.
 
HIV-1 Infection Assays.
 
The infection assays
 
 
 
were performed
as described previously (1, 2). Pseudotyped HIV-1 stocks were
generated by calcium phosphate transfections of HEK293T cells
with the proviral vector plasmid NL-Luc-E
 
-
 
R
 
2
 
 containing a fire-
fly luciferase reporter gene (14) and expression plasmids for either
ADA or JRFL gp160 envelopes. Viral stocks were evaluated by
limiting dilution on GHOST CXCR4/CCR5 and 293T-CD4-
CCR5 cells. In HIV-1 cell capture assays, DC-SIGN or L-SIGN
expressing THP-1 transfectants (250,000 cells) were preincubated
with pseudotyped HIV-1 (multiplicity of infection 
 
z
 
0.1 with re-
gard to target cell concentration) in a total volume of 0.5 ml for
3 h to allow cellular adsorption of the virus. After 3 h incubation,
cells were washed with 2 vol PBS and the THP-1 transfectants
were cocultured with Hut/CCR5 targets (100,000 cells) in the
presence of 10 
 
m
 
g/ml polybrene in 1 ml cell culture medium.
Cell lysates were obtained after 3 d and analyzed for luciferase ac-
tivity. In contrast, HIV-1 enhancement assays used suboptimal
concentrations of virus (typically 
 
,
 
0.05 multiplicity of infection)
without a wash step. In brief, 
 
DC-SIGN
 
 or 
 
L-SIGN
 
 transfectants
(50,000 cells) were incubated with identical virus concentrations
(either pseudotyped HIV-1 or replication-competent M-tropic
strain HIV-1
 
JR-CSF
 
), and after 2 h activated T cells (100,000 cells)
were added. Cell lysates were obtained after several days and ana-
lyzed for either luciferase activity or p24 antigen levels. T cells
were activated by culturing them in the presence of 10 U/ml IL-2
and 10 
 
m
 
g/ml PHA for 2 d.
 
Immunohistochemical Analysis.
 
Staining of the tissue cryosec-
tions was performed as described previously (2). 8-
 
m
 
m
 
 
 
cryosec-
 
tions of the tissues were fixed in 100% acetone for 10 min,
washed with PBS, and incubated with the first antibody (10 
 
m
 
g/
ml) for 60 min at 37
 
8
 
C. After washing, the final staining was per-
formed with the ABC-PO/ABC-AP Vectastain kit (Vector Lab-
oratories) according to the manufacturer’s protocol. Nuclear
staining was performed with hematoxylin.
 
Results
 
Genomic Map of DC-SIGN and L-SIGN.
 
A fine map of
the 
 
DC-SIGN/L-SIGN
 
 gene locus was determined using
information from the human BAC clone CTD-2102F19
sequence, which is now available in GenBank/EMBL/
DDBJ (accession no. AC008812; Fig. 1). DC-SIGN and
L-SIGN are positioned in a head-to-head orientation 15.7
kb apart. RH mapping indicated that DC-SIGN and
L-SIGN are located on chromosome 19p13.2-3, near the
marker D19S912 (lod score values .11.1) with DC-SIGN
positioned more telomeric. In agreement with the RH
data, the D19S912 marker is found at a distance of z37 kb
centromeric to L-SIGN on the BAC sequence.
Soilleux et al. (5) reported a DC-SIGNR cDNA clone
that contained eight exons with an additional 39 intron
spliced out of the 39 untranslated region (UTR) compared
with the cDNA clone described by Yokoyama-Kobayashi
et al. (4). Our RT-PCR experiments on different tissues
(liver, pancreas, lung, and placenta) showed that the splice
variant described by Soilleux et al. is consistently present
but only as a minor transcript, whereas the major transcript
consists of seven exons (data not shown). Also, a transcript
missing exons 2 and 6, as described by Yokoyama-Koba-
yashi et al. (4), was extremely rare in our hands.
Northern hybridization data (see below) indicated that
DC-SIGN mRNA is 3 kb longer than that reported previ-
ously (3, 5). We found that this difference is due to the
presence of an additional 3-kb UTR in exon 7. Indeed,
there was no canonical polyadenylation signal in either of
the previously published DC-SIGN cDNA sequences, and
a search of GenBank/EMBL/DDBJ sequences revealed
short polyadenylated ESTs with putative poly(A) signal
Figure 1. Schematic representation of the DC-SIGN/L-SIGN genetic
map. Physical distances and gene orientation are based on the sequence
provided from BAC clone CTD-2102F19 (GenBank/EMBL/DDBJ ac-
cession no. AC008812).674 Expression and Functional Characterization of a DC SIGN–related Protein
motifs mapping 3 kb downstream of the alleged 39 end of
DC-SIGN. RT-PCR experiments indicated that those
ESTs correspond to DC-SIGN mRNA (data not shown).
Based on these findings, we conclude that the full DC-
SIGN transcript contains the additional 3 kb, resulting in a
total of 4.3 kb.
Polymorphism in Exon 4 of L-SIGN. Exon 4 of both
DC-SIGN and L-SIGN contains repeats of 69 bp that en-
code repeating units of 23 amino acids. These repeats form
a neck between the carbohydrate recognition domain and
the transmembrane domain of the SIGN molecules. The
L-SIGN cDNA clone isolated from placental mRNA con-
tained the entire coding region of the gene, but only six full
repeats were present in the sequence corresponding to exon
4, in contrast to seven full repeats identified in the cDNA
reported by Soilleux et al. (5). This indicated that the repeat
region of L-SIGN is polymorphic. Analysis of exon 4 in
350 Caucasian individuals showed the presence of seven al-
leles based on number of repeats (ranging from three to
nine), the most common of which was the allele containing
seven repeats (Table I). Strikingly, analysis of DC-SIGN
exon 4 in 150 Caucasians did not reveal any variability.
Northern Blot Analysis of DC-SIGN and L-SIGN. L-SIGN
mRNA exhibits z90% similarity to DC-SIGN mRNA
over the entire coding region, but there is only 53% simi-
larity between exons 2 of the genes. Therefore, exon 2
sequence was used to generate a probe (84 nt) that was
L-SIGN specific in Northern blot analysis. The probe hy-
bridized to mRNA of z1.9, 2.6, and 4.2 kb in size in liver
and lymph node, and a weak 1.9-kb band was detected in
thymus (Fig. 2 A). The 1.9-kb band, which is prominent in
lymph node and fetal liver, corresponds to the predicted
size of L-SIGN. The upper bands (one of which, 2.6 kb, is
substantial in adult liver) are likely to be alternative tran-
scripts, but RACE and RT-PCR techniques have not in-
dicated the presence of UTRs varying in length nor alter-
native splice variants. Therefore, we cannot exclude the
possibility that a gene(s) with homology to L-SIGN and
precisely the same expression pattern is present in humans,
but a thorough search for such genes in the sequence data-
bases has been unsuccessful. Finally, a polymorphism in the
L-SIGN gene (e.g., exon 4 repeat expansion or alteration
in the polyadenlation signal motif) could possibly explain
the larger transcript size.
Northern blots were reprobed with a 1.2-kb fragment
containing the entire coding sequence of DC-SIGN,
which recognizes both DC- and L-SIGN mRNA due to
their high sequence similarity (Fig. 2 B). Once again, the
bands representing L-SIGN transcripts were observed in
liver, lymph node, and fetal liver. Additionally, a 4.3-kb
transcript representing DC-SIGN was detected in mono-
cyte-derived DCs and lymph node, and to a lesser extent,
in placenta, spleen, thymus, and possibly liver.
L-SIGN mRNA was also detected in placenta and DCs
using a more sensitive RT-PCR technique, in agreement
with previously reported data (5), but the level of expres-
sion in these tissues is too low to be detected by Northern
hybridization. The probe which recognizes both DC-
SIGN and L-SIGN transcripts with nearly equal sensitivity
clearly indicated differential tissue distribution of the two
gene products: L-SIGN is primarily transcribed in liver and
lymph node, whereas DC-SIGN is specifically expressed in
DCs and tissues that accommodate DCs (Fig. 2; reference
1). Although both L-SIGN and DC-SIGN mRNAs are
found in lymph node, it is likely that they are expressed by
different cell types in this tissue. DCs, which are frequent
in lymph node, are the source of DC-SIGN mRNA in this
tissue (2), but L-SIGN mRNA is not detected by Northern
blot analysis in DCs, peripheral blood lymphocytes, or
spleen (Fig. 2). It is possible that L-SIGN expression may
be inducible in certain leukocytes during specific stages of
activation or, perhaps more likely, endothelial cells of the
lymph node may constitutively express this receptor. Char-
Table I. Polymorphism of the Repeat Region in L-SIGN Exon 4
No. of repeats Allele frequency (percent)
3 1 (0.3)
4 25 (3.6)
5 202 (28.9)
6 86 (12.2)
7 377 (53.9)
8 2 (0.3)
9 7 (1.0)
Figure 2. Northern blot analysis of DC-SIGN and L-SIGN. Positions
of the 4.3-kb (black arrows) and 1.9-kb (white arrows) sizes are marked
on the left. (A) Hybridization with the L-SIGN–specific probe indicating
expression of the gene in liver, lymph node, and weakly in thymus. (B)
Hybridization with the probe recognizing both genes. 4.3-kb bands rep-
resent DC-SIGN mRNA. The light upper band (z4.2 kb) evident in
liver and lymph node using the L-SIGN–specific probe (Fig. 3 A) is dis-
tinct from DC-SIGN mRNA (4.3 kb) due to the specificity of the probe,
intensity patterns, and slight differences in size. (C) Reprobing of the
blots with the b-actin cDNA control probe.675 Bashirova et al.
acterization of the mechanism involved in the differential
tissue expression of these two highly homologous mole-
cules will be of particular interest.
L-SIGN Is Expressed by Human LSECs and Not by DCs.
To identify the cells expressing L-SIGN molecules in vivo,
we performed immunohistochemical analysis using a pair of
anti–DC-SIGN mAbs, one of which, AZN-D3, cross-
reacted with L-SIGN, whereas another, AZN-D1, was
DC-SIGN specific (Fig. 3 A). As expected from the North-
ern blot analysis, poor staining of liver tissue was observed
using the DC-SIGN–specific mAb AZN-D1 (Fig. 3 B), and
the rare cells detected with this antibody are probably DCs
residing in liver. In contrast, the mAb AZN-D3 brightly
stained cells lining the sinusoids of the liver (Fig. 3 B). mAbs
against the endothelial cell–specific marker CD31 gave a
similar staining pattern on serial liver sections (data not
shown), suggesting that L-SIGN is expressed by LSECs. To
support this idea, primary human LSECs were distinguished
from the other hepatic cells by uptake of OVA, which is a
unique characteristic of LSECs (15), and were tested for ex-
pression of L-SIGN directly. Staining of LSECs with poly-
clonal anti–L-SIGN antibodies indicated that L-SIGN is ex-
pressed exclusively by these cells in liver (Fig. 3 C).
Both AZN-D1 and AZN-D3 stained lymph node
equally well (data not shown), but without sufficient defi-
nition to determine whether cellular staining patterns
differed between the two antibodies. However, using
L-SIGN–specific polyclonal antibodies, we found that
L-SIGN is not expressed by monocyte-derived DCs (Fig.
3 D), which supports conclusions from the Northern
blot analysis. Therefore, it is likely, that DC-SIGN and
L-SIGN are expressed by different types of cells in the
lymph node.
L-SIGN Binds ICAM-3 and HIV-1 gp120. We pre-
dicted that L-SIGN and DC-SIGN would bind similar
ligands given the nearly identical amino acid sequence of
their extracellular domains. Both ICAM-3 and HIV-1MN
gp120 have been shown to bind with high affinity to DC-
SIGN in a Ca21-dependent manner (1–3). Using a flow
cytometry–based adhesion assay (11), K562 cells transfected
Figure 3. L-SIGN is ex-
pressed on LSECs and not on
monocyte-derived DCs. (A) The
antibody AZN-D1 is DC-SIGN
specific, whereas AZN-D3
cross-reacts with L-SIGN. Stable
DC-SIGN and L-SIGN K562
transfectants were stained with
either AZN-D1 or AZN-D3.
(B) Immunohistochemical analy-
sis of DC-SIGN and L-SIGN
expression in the human liver.
Serial sections were stained with
either AZN-D1 (DC-SIGN spe-
cific) or with AZN-D3 (detects
both DC-SIGN and L-SIGN).
AZN-D1 stains infrequent cells
that may be DCs (arrows),
whereas AZN-D3 stains cells
lining sinusoids. (C) Expression of L-SIGN in liver is restricted to LSECs. 1 d after isolation, primary human liver cells were incubated with fluoro-
chrome-labeled OVA. L-SIGN expression was determined by indirect immunofluorescence using an L-SIGN–specific polyclonal antibody. Cells that
have taken up OVA (LSECs) and those that did not take up OVA (hepatocytes and other resident hepatic cells) are represented by solid and broken lines,
respectively, by gating on the respective cell populations. 2 3 105 cells were analyzed. (D) L-SIGN is not expressed by monocyte-derived DCs. Imma-
ture DCs, cultured from monocytes in the presence of GM-CSF and IL-4, do not stain with anti–L-SIGN polyclonal antibody, as determined by FAC-
Scan™ analysis. Solid line indicates staining with anti–L-SIGN polyclonal serum, whereas broken line (hidden under solid lane) represents staining with
rabbit preimmune serum.676 Expression and Functional Characterization of a DC SIGN–related Protein
with L-SIGN were shown to bind ICAM-3 with high
affinity (Fig. 4 A). The L-SIGN–mediated binding was
inhibited by the DC-SIGN/L-SIGN–specific mAbs
AZN-D2  and AZN-D3, mannan, or EGTA, but not by
the DC-SIGN–specific mAb AZN-D1, demonstrating that
L-SIGN functions as a mannose-binding C-type lectin
with a high affinity for ICAM-3. As predicted by the high
homology to DC-SIGN, L-SIGN was also able to bind to
HIV-1MN gp120 in a manner similar to that observed for
DC-SIGN (1) (Fig. 4 B). Mock transfected cells did not
bind either ICAM-3 or HIV-1MN gp120 (data not shown).
L-SIGN Enhances HIV-1 Infection. High affinity bind-
ing of L-SIGN to HIV-1 gp120 raised the possibility that,
like DC-SIGN, L-SIGN might bind infectious HIV-1 and
enhance infection of target cells in trans. To test the role of
L-SIGN as a transreceptor in HIV-1 infection, THP-1 cells
expressing either DC-SIGN or L-SIGN were pulsed with
single round infectious HIV-luciferase pseudotyped with
M-tropic HIV-1JRFL envelope glycoprotein, washed to re-
move unbound virus, and incubated with target cells permis-
sive for HIV-1 infection. Infection was evaluated after 3 d.
Both the L-SIGN– and DC-SIGN–transfected THP-1 cells
captured infectious HIV-1 and transmitted the virus to target
cells, while mock transfected THP-1 cells did not (Fig. 5 A).
Next we investigated whether L-SIGN would be able to
capture a limiting concentration of HIV-1 and efficiently
present the virus to the permissive cells promoting infection.
HEK293T cells expressing DC-SIGN or L-SIGN, or mock
Figure 4. L-SIGN binds ICAM-3 (A) and HIV-1
gp120 (B). Adhesion of ICAM-3 and gp120 to the
K562–L-SIGN and K562–DC-SIGN cells was
measured with the fluorescent bead adhesion assay
(reference 11). The y-axis represents the percent-
age of cells binding ligand-coated fluorescent
beads. The L-SIGN cross-reacting mAbs AZN-D2
(20 mg/ml) and AZN-D3 (20 mg/ml) inhibit the
adhesion of ICAM-3 and gp120 to L-SIGN, in
contrast to the DC-SIGN–specific mAb AZN-D1
(20 mg/ml). Adhesion of both ICAM-3 and gp120
to the K562 transfectants is also inhibited by either
20 mg/ml mannan or 5 mM EGTA. Adhesion of
both ligands to mock transfectants was ,5%. One
representative experiment out of three is shown
(SD  ,  5%).
Figure 5. L-SIGN captures and enhances infection of T cells with HIV-1 in trans. (A) L-SIGN captures HIV-1 and transmits it to target cells. Stable
DC-SIGN– or L-SIGN–expressing THP-1 transfectants were preincubated with HIV-luc/JRFL pseudovirions to allow capture of the virus. Cells were
washed and THP-1 transfectants were cocultured with Hut/CCR5 target cells. Cell lysates were obtained after 3 d and analyzed for luciferase activity.
For each of the coculture conditions employed, mock infected controls were uniformly ,100 cps in activity. Each data set represents the mean of four
separate wells of infected cells. One representative experiment out of two is shown. (B) L-SIGN enhances infection of T cells by pseudotyped HIV-1.
HEK293T cells were transiently transfected with cDNA encoding DC-SIGN, L-SIGN, or empty vector. Control cells were preincubated with 20 mg/
ml AZN-D2 or 20 mg/ml mannan. Low amounts of pseudotyped HIV-1ADA were added together with activated T cells as described previously (refer-
ence 1). Infectivity was determined after 2 d by measuring luciferase activity. One representative experiment of two performed is shown. Each experi-
ment was done in triplicate wells. (C) L-SIGN enhances infection of T cells by replication competent HIV-1. Stable K562 transfectants of both L-SIGN
and DC-SIGN were incubated with low virus concentrations of replication-competent M-tropic strain HIV-1JR-CSF (TCID50 100/ml). To determine the
specificity, cells were preincubated with AZN-D2 (20 mg/ml). After 2 h, activated T cells were added as described previously (reference 2). Culture su-
pernatants were collected at day 14 after K562-T cell coculture and HIV-1 production was measured using ELISA to determine p24 antigen levels. In
control experiments, the same amount of virus was added directly to T cells. One representative experiment out of three is shown. Each data set repre-
sents the mean of three separate wells of infected cells.677 Bashirova et al.
transfected cells were incubated with low titers of HIV-
luciferase pseudotyped with HIV-1ADA envelope glyco-
protein. The unwashed cells were then cocultured with
activated T cells. Minimal infection of target cells was ob-
served from mock transfected HEK293T cells pulsed with
HIV-1 (Fig. 5 B). However, HEK293T cells transfected
with L-SIGN enhanced HIV-1 infection of T cells in trans,
similar to DC-SIGN (Fig. 5 B). The DC-SIGN–mediated
enhancement was inhibited with the cross-reactive AZN-D2
antibody, while partial inhibition was observed for L-SIGN,
possibly because of some difference in the reactivity of this
antibody to the two SIGN molecules that was evident under
the conditions employed in this experiment. Mannan effi-
ciently inhibited enhancement by both SIGN molecules.
Similar experiments to evaluate the ability of L-SIGN to
enhance HIV-1 infection of T cells were performed using
replication-competent virus. K562 cells transfected with
L-SIGN, DC-SIGN, and empty vector were incubated
with the M-tropic HIV-1JR-CSF strain at low virus concen-
trations for 2 h and subsequently cocultured with activated
T cells (Fig. 5 C). No viral replication was observed using
mock transfected K562 cells, while L-SIGN transfectants
transmitted HIV-1 to target cells, resulting in viral replica-
tion with nearly the same efficiency as DC-SIGN transfec-
tants. Almost complete inhibition of HIV-1 replication with
the DC-SIGN/L-SIGN–specific antibody AZN-D2 indi-
cated the specificity of these receptors to enhance HIV-1
infection. Thus, non-DC lineage cells expressing L-SIGN
within liver and possibly in lymph node may also have the
ability to capture and transmit HIV-1 to lymphocytes.
Discussion
The homologous human C-type lectins DC-SIGN and
L-SIGN appear to be the products of a recent gene dupli-
cation. The corresponding proteins share the same domain
organization and overlapping, if not completely identical,
ligand specificity. The most diverse region of these mole-
cules occurs in their cytoplasmic tails (5). It has been sug-
gested that DC-SIGN–associated HIV-1 may be internal-
ized, protecting it from degradation or inactivation (1). If
so, the sequence variation in the cytoplasmic region of
L-SIGN relative to DC-SIGN could affect the level of re-
ceptor internalization and viral uptake, perhaps explaining
the consistent differences in efficiency of HIV-1 infection
enhancement observed in our experiments between DC-
SIGN and L-SIGN transfectants (Fig. 5).
Another obvious difference in SIGN genes is the repeat
polymorphism in exon 4 of L-SIGN, which is conserved in
DC-SIGN (Table I). The neck domain of L-SIGN may
contain from three to nine repeats, while DC-SIGN always
consists of seven repeats among the Caucasians tested. It is
not clear whether the differences in exon 4 diversity of
these genes is because of some distinction in the physical
feature(s) of the genes or to selective processes acting on the
genes differentially. The neck domain may be involved in
oligomerization of the receptors (5) and variable numbers
of repeats could potentially affect functional characteristics
of the L-SIGN molecule, particularly in heterozygotes
where heterooligomers might be present. However, our
preliminary data indicated no difference between L-SIGN
molecules containing six or seven repeats in ligand binding
or in HIV-1 capture and enhancement experiments.
Although the SIGN genes have maintained sequence
and functional similarity over their evolutionary history,
regulatory elements determining their tissue distribution
have evolved along unique paths. Northern blot analysis of
mRNA expression clearly indicated expression of DC-
SIGN in monocyte-derived DCs and in tissues where DCs
reside, whereas expression of L-SIGN in DCs was unde-
tectable (Fig. 2). Further, L-SIGN was not detected
on monocyte-derived DCs using antibodies specific
to L-SIGN (Fig. 3 C). Thus, it is most likely that unique
cell types in the lymph node express one but not both
SIGN molecules: L-SIGN could be expressed by endothe-
lial cells, as it is in liver, whereas DC-SIGN is expressed by
DCs in the T cell area of lymph node (2).
Liver sinusoids are specialized capillary vessels character-
ized by the presence of resident macrophages adhering to
the endothelial lining. The LSEC–leukocyte interactions,
which require expression of adhesion molecules on the cell
surfaces, appear to constitute a central mechanism of pe-
ripheral immune surveillance in the liver (15). The man-
nose receptor as well as other costimulatory receptors such
as MHC class II, CD80, and CD86, are known to be ex-
pressed on LSECs and to mediate the clearance of many
potentially antigenic proteins from the circulation in a
manner similar to DCs in lymphoid organs (15). L-SIGN
may fit in this category of receptors on LSECs, as its tissue
location and ligand-binding properties strongly implicate a
physiologic role for this receptor in antigen clearance, as
well as in LSEC–leukocyte adhesion. The high expression
of ICAM-3 on apoptotic cells (16) may provide the means
by which these cells are trapped by L-SIGN–expressing
cells in the liver and subsequently cleared.
The mannose glycans present on gp120 appear to medi-
ate HIV-1 adhesion to the SIGN molecules, although the
contribution of the gp120 polypeptide backbone is not ex-
cluded (1). Several in vitro studies have shown that highly
glycosylated HIV-1 gp120 is a strong ligand for a variety of
mannose-binding lectins (17–22). Although the carbohy-
drate structures on the HIV envelope could be nonspecifi-
cally recognized by host lectins, the physiological conse-
quences of such recognition will be specified by the
functions of the binding molecule. The SIGN molecules
are the first membrane-associated lectins identified to date
that enhance HIV-1 infection. Interestingly, the expression
of L-SIGN in liver sinusoids suggests that LSECs, which
are in continual contact with passing leukocytes, can cap-
ture HIV-1 from the blood and promote transinfection of
T cells. Moreover, prior studies have indicated that LSECs
themselves may be susceptible to HIV-1 infection (23, 24).
Thus, it is possible that L-SIGN promotes infection of
these cells, thereby establishing a reservoir for production
of a new virus to pass on to T lymphocytes trafficking
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Additional functional studies are necessary for under-
standing the normal physiologic role of L-SIGN and its
possible role in HIV-1 pathogenesis. Its ability to enhance
transinfection of T cells suggests that L-SIGN may contrib-
ute to HIV-1 susceptibility. Alternatively, if a physiologic
function of L-SIGN involves antigen clearance, this recep-
tor could play a protective role in clearance of the virus
from the circulation. A clearer understanding of this recep-
tor may provide insight into its potential use in novel ther-
apy against HIV-1.
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